Shortage of Conivaptan Hydrochloride Injection
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
Conivaptan Hydrochloride Injection is currently in shortage due to delays in shipping, with the only manufacturer reporting it as unavailable.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 7, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Conivaptan Hydrochloride Injection.
What's in Shortage
The generic drug name is Conivaptan Hydrochloride Injection. There are no brand names listed. The dosage form is Injection, and the current status is an ongoing shortage. It falls under the therapeutic category of Cardiovascular. The shortage was first posted on 03/14/2022 and last updated on 04/01/2026.
Which Manufacturers Are Affected
- Cumberland Pharmaceuticals Inc.: This manufacturer has the drug unavailable. The presentation is Vaprisol Dextrose In Plastic Container, Injection, 20 mg/100 mL (NDC 66220-160-10). Contact information: 615-255-0068.
Why There's a Shortage
The shortage is due to a delay in shipping of the drug. No additional details were provided.
What Patients Should Do
Patients should talk to their pharmacist about the availability of this medication and ask about possible alternatives without specifics. They can also contact the manufacturer directly. Remember, patients should consult their healthcare provider for any personalized advice and not make changes to their treatment without professional guidance.
Source
This information is from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Nationwide notices with similar length or severity timing 8
Two Areazine-derived peer sets for this FDA drug-shortage notice: nearest notices by body length and by same severity near the same agency date. Peers come from other categories so they are not the same-feed Related list above.
Similar body length
Nearest notices by article body length (1,144 characters here).
Similar severity timing
Same severity (high) notices issued closest in time to April 7, 2026.
Frequently Asked Questions
Common questions about this FDA drug-shortage notice.